Celularity (CELU) Long-Term Deferred Tax (2018 - 2025)
Celularity (CELU) posted quarterly Long-Term Deferred Tax of $12000.0 for Q4 2025, up 33.33% year-over-year from $9000.0 in Q4 2024, and up 33.33% quarter-over-quarter from $9000.0 in Q4 2024.
Celularity (CELU) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Long-Term Deferred Tax for 4 consecutive years, with $12000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 33.33% year-over-year to $12000.0; the TTM figure through Dec 2025 stood at $12000.0 (up 33.33% YoY), while the FY2025 annual figure was $12000.0, up 33.33% from the prior year.
- Long-Term Deferred Tax improved to $12000.0 in Q4 2025 per CELU's latest filing, from $9000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $12000.0 in Q4 2025 and bottomed at $9000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2019 | 1,653.00 |
| Dec 31, 2018 | 149,750.00 |